## EXAS: Exact Sciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0); RSI 90 overbought. Stock is in no-man's land without clear edge. Caution: overbought RSI (90).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($98.10)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS**
- Source: Business Wire | 20251212T040909 | Bullish | Relevance: 100%
- Exact Sciences, in collaboration with the NSABP Foundation and the German Breast Group, announced positive clinical study results for its Oncodetect® molecular residual disease (MRD) test in early triple-negative breast cancer (TNBC). The study, presented at SABCS, showed that the Oncodetect test powerfully predicts distant recurrence after surgery in TNBC patients. The data highlights the test's potential to guide post-surgical treatment decisions and identify high-risk patients.

**2. Exact Sciences stock reaches 52-week high at 101.89 USD**
- Source: Investing.com | 20251210T161005 | Bullish | Relevance: 100%
- Exact Sciences Corporation (EXAS) has achieved a new 52-week stock high of $101.89, marking significant growth over the past year and six months. This surge in value is underpinned by strong investor confidence and analyst predictions of profitability, despite the stock potentially trading above its Fair Value according to InvestingPro analysis. Recent news includes Abbott Laboratories' plan to acquire Exact Sciences for approximately $23 billion, prompting several analyst downgrades to "Hold" with price targets aligning with the proposed acquisition price, expected to close by Q2 2026.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-28 | Stifel | $105 | $80 | +31% |
| 2025-11-25 | Canaccord Genui | $105 | $85 | +24% |
| 2025-11-24 | Benchmark | $0 | $0 | 0% |
| 2025-11-24 | Jefferies | $105 | $90 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-28 | Stifel | down | Hold |
| 2025-11-25 | Canaccord Genui | down | Hold |
| 2025-11-24 | Benchmark | down | Hold |
| 2025-11-24 | Jefferies | down | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($1.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- FMR, LLC: 9.8% (-30.6%)
- Vanguard Group Inc: 9.4% (-0.5%)
- Capital World Invest: 8.5% (-11.3%)
- Blackrock Inc.: 5.6% (+0.3%)
- Wellington Managemen: 2.8% (-55.6%)

### Key Risks

1. Overbought RSI (90) with bearish MACD signals exhaustion.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +26%) could attract flows.
- Momentum building: MRS_10 improving +2.6% over 5 days suggests accumulation.

### Fundamentals

Forward P/E 90.8x attractive for 231% earnings growth. Balance sheet: strong liquidity (2.7x). Analyst sentiment positive (5 raises, avg +26%). Insider selling cluster ($1.7M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.3B |
| Beta | 1.42 |
| 52W Range | $38.81 - $101.95 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.07 |
| Forward P/E | 90.8 |
| Current P/E | 300.2 |
| YoY Growth | 230.6% |
| EPS Direction | FALLING |

### Technicals

MRS_10 strengthening from -1.1% to 1.5% (+2.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 at 1.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.86), momentum weakening. RSI overbought at 90, risk of mean reversion. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.50% (CS: 47) | Neutral |
| RSI_14 | 89.6 | Overbought |
| MACD Histogram | -0.86 | Bearish |
| vs SMA20 | 1.064x | Above |
| vs SMA50 | 1.333x | Above |
| vs SMA200 | 1.801x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.50
- **Stop Loss:** $98.10 (3.3% risk)
- **Target:** $104.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 294
- **Position Value:** $29,841.00
- **Portfolio %:** 29.84%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-25 (Est: $0.08)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.16 | $0.24 | +49.5% |
| 2025Q2 | $0.05 | $0.10 | +84.9% |
| 2025Q1 | $-0.10 | $-0.36 | -276.9% |
| 2024Q4 | $-0.19 | $-0.06 | +67.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*